GILD Trading Analysis - 10/23/2026 12:51 PM — TRU-SENTIMENT

News Headlines & Context

Gilead Sciences (GILD) has seen multiple recent developments that provide context for the trading data below. The following items are based on general knowledge and are separated from the data-driven analysis:

• GILD's HIV prevention drug lenacapavir (Yeztugo) received expanded FDA approval for broader PrEP use, potentially expanding its multi-billion dollar market opportunity.
• The company reported Q2 2026 earnings with oncology and liver disease franchises showing steady growth, partially offsetting legacy HIV drug pricing pressure.
• Gilead announced a new share repurchase authorization and maintained its dividend of $3.28 annually (ex-dividend dated 2026-09-15).
• Analysts noted upcoming pivotal data readouts in inflammatory diseases expected before year-end 2026 as a potential catalyst.
• Broader biotech sector sentiment improved on positive regulatory signals, which may support large-cap pharma like GILD.

Context: These fundamental and pipeline catalysts align with the bullish options flow and upward price trend seen in the embedded data, though the news is not part of the strict data analysis that follows.

Fundamental Analysis

Based strictly on the provided FUNDAMENTALS data for GILD:

• Trailing P/E: 17.70; Trailing EPS: -2.60 (negative earnings, indicating an accounting net loss over the trailing period despite positive operational segments).
• Dividend Yield: 2.10% with Dividend Rate of $3.28 and ex-dividend date 2026-09-15, showing income return.
• Market Cap: $194,338,147,150.00; Shares Outstanding: 1,239,955,000.00; Institutional Ownership: 67.61%.
• Beta: 0.03 (extremely low market sensitivity); 52-Week High: $160.51; 52-Week Low: $114.02.
• Average Volume: 5,643,000.00; Historical Volatility: 24.46%.
• Forward P/E, PEG Ratio, Price/Book, Revenue Growth, Profit Margins, ROE, Debt/Equity, and Free Cash Flow are all null/unavailable in the data.
• Analyst consensus and target price are null; no recommendation key provided.

Fundamentals show a large-cap biotech with low beta and a paying dividend, but negative trailing EPS. Valuation via trailing P/E of 17.70 cannot be compared to peers due to missing PEG/sector data. The low beta and institutional ownership contrast with the upward technical momentum and bullish options sentiment, suggesting the price strength is not driven by fundamental earnings growth in the embedded data.

Current Market Position

From the embedded daily and minute data: Current price (2026-10-22 close) is $156.73. Recent daily action shows a rise from $143.72 (2026-09-11) to a 30-day high of $160.51 (2026-10-15) then a pullback to $153.76 (2026-10-19) and recovery to $156.73. The last minute bars (2026-10-22 15:55) closed at $157.15 on volume of 226,281, up from $156.59, indicating late-session intraday buying momentum. Key observational levels: 30-day low $142.60, 30-day high $160.51, prior day close $154.19.

Technical Analysis

SMA alignment: Price ($156.73) > SMA 5 ($155.31) > SMA 20 ($150.71) > SMA 50 ($148.46), confirming bullish stacked crossovers. RSI 14 at 68.86 shows strong momentum near overbought (70 threshold). MACD (2.48) above signal (1.98) with positive histogram (0.50) confirms bullish momentum. Price is within Bollinger Bands ($142.24–$159.18), near upper band, no squeeze (expansion visible). 30-day range: low $142.60, high $160.51; price at $156.73 is ~83% up the range.

True Sentiment Analysis (Delta 40-60 Options)

From the True Sentiment Options data (methodology: Delta 40-60 only):

Call Dollar Volume: $301,060.00 (65.0%) Put Dollar Volume: $162,035.00 (35.0%) Total: $463,095.00

Sentiment: Bullish. Call contracts 304 vs put 188; call trades 34 vs put 10. Pure directional conviction shows 65% call dollar volume, indicating bullish near-term expectations. No divergence from technicals (both bullish). Options flow supports continuation toward $159–$160 zone.

Key Price Levels (Observational Only)